SALT LAKE CITY—Mirza Mansoor Raza, a director at Sera Prognostics, Inc. (NASDAQ:SERA), recently sold a small portion of the company's Class A Common Stock. According to a filing with the Securities and Exchange Commission, Raza sold 93 shares on December 6th at a price of $7.12 per share, totaling $662. The transaction comes as SERA's stock has shown strong momentum, with a 69% gain over the past year and nearly 9% increase in the past week.
The transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). This sale was not a discretionary action by Raza but rather a mandated transaction by Sera Prognostics to satisfy tax requirements.
Following the sale, Raza holds 6,636 shares of Sera Prognostics. The company, based in Salt Lake City, specializes in medical laboratory services.
In other recent news, Sera Prognostics revealed its Q3 financials, reporting a decrease in net revenue to $29,000 from the previous year's $42,000. The company also experienced a rise in operating expenses by 8% to $8.9 million and a 10% increase in net loss to $7.9 million. Despite these financial challenges, Sera Prognostics is making strides in enhancing the adoption of its PreTRM test, which aims to tackle the issue of rising preterm birth rates in the U.S. The company has seen a 227% surge in website traffic, thanks to increased accessibility and educational campaigns. CEO Evguenia Lindgardt underscored the importance of the upcoming PRIME clinical study results in securing payer support. These recent developments indicate that Sera Prognostics is focusing on commercial growth and maintaining solid cash reserves into 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.